| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Frank Tacke | Q62748536 |
| Linda Hammerich | Q82224121 | ||
| P2860 | cites work | Evolutionary divergence and functions of the human interleukin (IL) gene family | Q21245454 |
| IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines | Q24294720 | ||
| Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling | Q27002391 | ||
| Gp130 and the interleukin-6 family of cytokines | Q28237653 | ||
| IL-22 increases the innate immunity of tissues | Q28276850 | ||
| IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system | Q28585033 | ||
| IL-33 reduces the development of atherosclerosis | Q28594104 | ||
| Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production | Q29614596 | ||
| Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation | Q29614840 | ||
| Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression | Q29615766 | ||
| Immunologic messenger molecules: cytokines, interferons, and chemokines | Q30449522 | ||
| An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response | Q33853821 | ||
| Interleukin-12 promotes pathologic liver changes and death in mice coinfected with Schistosoma mansoni and Toxoplasma gondii | Q34006279 | ||
| Chemokine receptor CCR6-dependent accumulation of γδ T cells in injured liver restricts hepatic inflammation and fibrosis. | Q34070116 | ||
| The molecular basis of T helper 1 and T helper 2 cell differentiation | Q34106569 | ||
| Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: Role of signal transducer and activator of transcription 3 | Q34163926 | ||
| Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity. | Q34491845 | ||
| Hepatic IL-17 responses in human and murine primary biliary cirrhosis | Q35575733 | ||
| Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts | Q35824711 | ||
| Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection | Q36062404 | ||
| Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice | Q36089631 | ||
| Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer | Q36404654 | ||
| Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice | Q36794471 | ||
| Inflammatory pathways in liver homeostasis and liver injury | Q37207091 | ||
| Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. | Q37311036 | ||
| Role of IL-17 and Th17 cells in liver diseases | Q37825436 | ||
| Deciphering and reversing tumor immune suppression. | Q38124437 | ||
| Role of gamma-delta T cells in liver inflammation and fibrosis. | Q38217236 | ||
| Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. | Q38344139 | ||
| STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. | Q38358871 | ||
| IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma. | Q39024081 | ||
| Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice | Q39333394 | ||
| Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model | Q39938317 | ||
| Interleukin-10 gene therapy reverses thioacetamide-induced liver fibrosis in mice | Q40393876 | ||
| Effect of IL-4 and IL-13 on collagen production in cultured LI90 human hepatic stellate cells | Q40444779 | ||
| Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation | Q40560155 | ||
| LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. | Q40910796 | ||
| Bone marrow-derived stem cells ameliorate hepatic fibrosis by down-regulating interleukin-17. | Q41853274 | ||
| Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis | Q41945735 | ||
| Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells | Q42448855 | ||
| The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury | Q42541847 | ||
| Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases | Q44493772 | ||
| IL-10 receptor and coreceptor expression in quiescent and activated hepatic stellate cells. | Q44713685 | ||
| Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent | Q44826352 | ||
| The regenerative activity of interleukin-6. | Q45885453 | ||
| Plasmodium berghei infection in mice induces liver injury by an IL-12- and toll-like receptor/myeloid differentiation factor 88-dependent mechanism | Q47894338 | ||
| Gender disparity of hepatocellular carcinoma: the roles of sex hormones. | Q51552877 | ||
| Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. | Q52543547 | ||
| Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. | Q53344106 | ||
| Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis. | Q54317622 | ||
| Lack of gp130 expression in hepatocytes promotes liver injury1 1K.L.S. and T.W. contributed equally to this work | Q57339931 | ||
| Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice | Q58535662 | ||
| Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice | Q58619570 | ||
| The biology of interleukin-6 in the 21st century | Q62658815 | ||
| Hepatic release of interleukin-10 during cardiopulmonary bypass in steroid-pretreated patients | Q64127379 | ||
| Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production | Q70527759 | ||
| Interleukin-10 regulation in normal subjects and patients with asthma | Q71120290 | ||
| IL-10 prevents liver necrosis during murine infection with Trichinella spiralis | Q73910734 | ||
| IFN-gamma, IL-12, and TNF-alpha are required to maintain reduced liver pathology in mice vaccinated with Schistosoma mansoni eggs and IL-12 | Q77436972 | ||
| Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis | Q77598613 | ||
| Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice | Q77598616 | ||
| Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3 | Q84365414 | ||
| Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease | Q85068847 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver disease | Q929737 |
| lessons learned | Q1673259 | ||
| chronic liver disease | Q5113984 | ||
| P304 | page(s) | 297-306 | |
| P577 | publication date | 2014-09-01 | |
| P1433 | published in | Clinical and Experimental Gastroenterology | Q5133804 |
| P1476 | title | Interleukins in chronic liver disease: lessons learned from experimental mouse models | |
| P478 | volume | 7 |
| Q92157142 | (-)-Catechin-7-O-β-d-Apiofuranoside Inhibits Hepatic Stellate Cell Activation by Suppressing the STAT3 Signaling Pathway |
| Q64269019 | A literature review for the mechanisms of stress-induced liver injury |
| Q39404643 | Adipokines in Liver Cirrhosis |
| Q64098409 | Adoptive Transfer of Bone Marrow-Derived Monocytes Ameliorates Schistosoma mansoni -Induced Liver Fibrosis in Mice |
| Q55208795 | Ambiguous roles of innate lymphoid cells in chronic development of liver diseases. |
| Q91989902 | Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution |
| Q36499677 | Cytokine levels contribute to the pathogenesis of minimal hepatic encephalopathy in patients with hepatocellular carcinoma via STAT3 activation |
| Q41500577 | Cytokines Genotype-Phenotype Correlation in Nonalcoholic Steatohepatitis. |
| Q52592866 | Deletion of sphingosine kinase 1 inhibits liver tumorigenesis in diethylnitrosamine-treated mice. |
| Q64229657 | Feasibility Analysis of Interleukin-13 as a Target for a Therapeutic Vaccine |
| Q26801150 | Fibrosis Related Inflammatory Mediators: Role of the IL-10 Cytokine Family |
| Q37390449 | Fish gut-liver immunity during homeostasis or inflammation revealed by integrative transcriptome and proteome studies |
| Q92874681 | Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function |
| Q36870030 | Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies |
| Q26771518 | Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step |
| Q28083001 | How Inflammation Impinges on NAFLD: A Role for Kupffer Cells |
| Q33722100 | Human Menstrual Blood-Derived Stem Cells Ameliorate Liver Fibrosis in Mice by Targeting Hepatic Stellate Cells via Paracrine Mediators |
| Q27025620 | IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression |
| Q58566658 | IL-33/ST2 Axis in Organ Fibrosis |
| Q58869848 | IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies |
| Q47554770 | Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. |
| Q41050095 | Induction of chronic cholestasis without liver cirrhosis - Creation of an animal model |
| Q45863196 | Interleukin-33 in the pathogenesis of liver fibrosis: alarming ILC2 and hepatic stellate cells |
| Q38753216 | Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy |
| Q99584925 | Internalization of Garlic-Derived Nanovesicles on Liver Cells is Triggered by Interaction With CD98 |
| Q35667925 | Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? |
| Q49959033 | Neutralization of IL-15 abrogates experimental immune-mediated cholangitis in diet-induced obese mice |
| Q26768588 | Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis |
| Q91962685 | Reduction of Fat to Muscle Mass Ratio Is Associated with Improvement of Liver Stiffness in Diabetic Patients with Non-Alcoholic Fatty Liver Disease |
| Q26782048 | Restoring homeostasis of CD4⁺ T cells in hepatitis-B-virus-related liver fibrosis |
| Q53126683 | The Effects of IL-22 on the Inflammatory Mediator Production, Proliferation, and Barrier Function of HUVECs. |
| Q89966619 | The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis |
Search more.